載入中
NASDAQHealthcareBiotechnology
最新資料
US$2.10
US$0.00 · 0.00%
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
收盤時
US$2.10
US$0.00 · 0.00%
盤後
US$2.10
US$0.00 · 0.00%
10月12日 下午4:10 ET
盤中時間採用ET。市場資料可能有所延遲。
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
日內區間
目前US$2.10
52週區間
目前US$2.10
盤中時間採用ET。市場資料可能有所延遲。
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
日內區間
目前US$2.10
52週區間
目前US$2.10
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 10萬 USD | 12萬 USD | 12.7萬 USD | 12.2萬 USD | 12.1萬 USD |
| 毛利 | −10萬 USD | −12萬 USD | −12.7萬 USD | −12.2萬 USD | −12.1萬 USD |
| 研究與開發 | 73.1萬 USD | 92.7萬 USD | 107.1萬 USD | 129萬 USD | 155.9萬 USD |
| 銷售、一般及管理費用 | 177.6萬 USD | 112.9萬 USD | 172.6萬 USD | 153.9萬 USD | 84.5萬 USD |
| 營業費用 | 250.7萬 USD | 205.6萬 USD | 279.7萬 USD | 282.9萬 USD | 240.4萬 USD |
| 利息收入 | 61萬 USD | 7000 USD | 5.6萬 USD | 5000 USD | 6000 USD |
| 利息支出 | 253.9萬 USD | 103.5萬 USD | 75.7萬 USD | 76.5萬 USD | 83.5萬 USD |
| 折舊和攤銷 | 10萬 USD | 12萬 USD | 12.7萬 USD | 12.3萬 USD | 12.2萬 USD |
| 營業利益 | −260.7萬 USD | −205.6萬 USD | −279.7萬 USD | −282.9萬 USD | −240.4萬 USD |
| 淨利 | −467.1萬 USD | −301.9萬 USD | −440萬 USD | −663萬 USD | −419.8萬 USD |
公司資料更新於 2026年10月12日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
報告持有此股票曝險的交易所交易基金。
iShares Biotechnology ETFIBB47.38萬0.00%108.2億 USD0.44%US$204.26-1.08%
Fidelity Nasdaq Composite Index ETFONEQ5.61萬—109.4億 USD0.21%US$107.36-0.42%
Invesco Nasdaq Biotechnology ETFIBBQ1.17萬0.01%1.12億 USD0.19%US$34.2482-1.07%
ProShares Ultra Nasdaq BiotechnologyBIB6134.10.01%9320.36萬 USD1.19%US$108.79-1.90%iShares Biotechnology ETFIBBFidelity Nasdaq Composite Index ETFONEQInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
